342 related articles for article (PubMed ID: 27060151)
21. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Peng L; Ye X; Zhou Y; Zhang J; Zhao Q
Support Care Cancer; 2015 Sep; 23(9):2813-24. PubMed ID: 25676487
[TBL] [Abstract][Full Text] [Related]
22. Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
Zhi WI; Ingram E; Li SQ; Chen P; Piulson L; Bao T
Integr Cancer Ther; 2018 Dec; 17(4):1079-1086. PubMed ID: 30027756
[TBL] [Abstract][Full Text] [Related]
23. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Cavaletti G; Jakubowiak AJ
Leuk Lymphoma; 2010 Jul; 51(7):1178-87. PubMed ID: 20497001
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics.
Kul AN; Ipek Y
J Oncol Pharm Pract; 2023 Oct; 29(7):1652-1660. PubMed ID: 36237141
[TBL] [Abstract][Full Text] [Related]
25. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
[TBL] [Abstract][Full Text] [Related]
26. Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK; Lonial S; Harvey RD
JCO Oncol Pract; 2023 Sep; 19(9):793-798. PubMed ID: 37418682
[TBL] [Abstract][Full Text] [Related]
27. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Vidisheva AP; Wang J; Spektor TM; Bitran JD; Lutzky J; Tabbara IA; Ye JZ; Ailawadhi S; Stampleman LV; Steis RG; Moezi MM; Swift RA; Maluso TM; Udd KA; Eshaghian S; Nassir Y; Berenson JR
Support Care Cancer; 2017 Oct; 25(10):3217-3224. PubMed ID: 28455546
[TBL] [Abstract][Full Text] [Related]
28. Foot drop in patients treated with bortezomib - a case series and review of the literature.
Vaxman I; Mauerman ML; Gatt ML; Berger T; Gertz MA
Leuk Lymphoma; 2022 Mar; 63(3):722-728. PubMed ID: 34702127
[TBL] [Abstract][Full Text] [Related]
29. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
30. Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
López M; Martínez Lacasa X; Martí JM; Muntañola A; Fernández M; Huertas S; Saumell S; De Diego I; Bustamante G; Mesa A; Canet M; Julià M; Vall-Llovera F
Leuk Lymphoma; 2017 Feb; 58(2):482-484. PubMed ID: 27348085
[No Abstract] [Full Text] [Related]
31. Bortezomib in newly diagnosed patients with multiple myeloma: A retrospective analysis from a tertiary care center in India.
Pragnya C; Linga VG; Thota NK; Gundeti S; Digumarti R
Indian J Cancer; 2015; 52(4):537-40. PubMed ID: 26960469
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.
Mu SD; Ai LS; Qin Y; Hu Y
Curr Med Sci; 2018 Feb; 38(1):43-50. PubMed ID: 30074150
[TBL] [Abstract][Full Text] [Related]
33. Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
Luczkowska K; Litwinska Z; Paczkowska E; Machalinski B
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29920472
[TBL] [Abstract][Full Text] [Related]
34. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
37. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
[TBL] [Abstract][Full Text] [Related]
38. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain.
Bechakra M; Nieuwenhoff MD; van Rosmalen J; Groeneveld GJ; Scheltens-de Boer M; Sonneveld P; van Doorn PA; de Zeeuw CI; Jongen JL
Mol Pain; 2018; 14():1744806918797042. PubMed ID: 30152246
[TBL] [Abstract][Full Text] [Related]
39. The safety of bortezomib for the treatment of multiple myeloma.
Cengiz Seval G; Beksac M
Expert Opin Drug Saf; 2018 Sep; 17(9):953-962. PubMed ID: 30118610
[TBL] [Abstract][Full Text] [Related]
40. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]